Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Standard BioTools ( (LAB) ).
On July 29, 2025, Standard BioTools Inc. announced that its Board of Directors approved restricted stock unit retention awards for its President & CEO, Michael Egholm, and CFO, Alex Kim, effective August 1, 2025. These awards, part of the company’s 2011 Equity Incentive Plan, aim to retain key executives by offering significant stock incentives contingent on continued employment. Additionally, the Human Capital Committee approved an increase in Mr. Kim’s annual performance bonus target to 80% of his base salary, effective January 1, 2025, highlighting the company’s commitment to rewarding its leadership.
The most recent analyst rating on (LAB) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The overall stock score reflects significant financial challenges, primarily due to persistent losses and high leverage. While technical indicators show moderate strength, valuation concerns persist with a negative P/E ratio. Strategic improvements and corporate events offer some potential for future growth. The company’s ability to improve operational efficiency and profitability will be crucial for enhancing its financial standing.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc. operates in the biotechnology industry, focusing on developing and providing advanced tools and technologies for life sciences research and clinical diagnostics.
Average Trading Volume: 1,917,378
Technical Sentiment Signal: Sell
Current Market Cap: $505.2M
For an in-depth examination of LAB stock, go to TipRanks’ Overview page.